Conferences
#ESHAL2024

4th How to Diagnose and Treat
Acute Leukaemias

‍

#ESHAL2024
Clinical Update
March 1-3, 2024
-
Stockholm, Sweden

Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock

‍

4th How to Diagnose and Treat
Acute Leukaemias

‍

Information

‍

ABOUT THE CONFERENCE:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address up to date diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. Intensive interaction between the speakers and participants will be helpful in spreading knowledge.Novel and still evolving insights into the biology and diagnosis of acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease. Recently updates on prognostication and classification of acute leukemias have been published which will be discussed in various sessionsThe programme of this “How to Diagnose and Treat: Acute Leukaemias” includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.

‍

SCIENTIFIC TOPICS:

• Diagnosis and treatment of rare diseases
• Novel treatments
• Dilemmas in AML
• Debate: MRD conversion before alloSCT
• Innovative trial designs to accelerate advances in leukaemia
• Immunotherapy in AML and ALL
• VenAza or intensive chemo as 1L treatment before allo HCT
• Debate: Transplant is no longer first line approach to Ph+ ALL
• Leukaemia treatment challenges
• Clonal haematopoiesis and germline predisposition

‍

Programme

Read the final programme!

CLICK HERE
ON-DEMAND CONTENT AVAILABLE
CLICK HERE

Corporate partners

With the support of*:
‍

Major Conference Partner
*******

‍

‍

‍Level 1 Conference Partners
*******

‍

‍

‍

‍

‍Level 2 Conference Partners
*******

‍

‍

‍Supporting Conference Partners
*******

‍
‍*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.

‍

Advancing haematology through international leading-edge disease- focused conferences.

Explore a portfolio of leading-edge scientific, translational research and clinically oriented meetings, designed to foster scientific exchange, practical insight, education and collaboration across clinical and research fields.
Explore all conferences